Home Archives 2014

Yearly Archives: 2014

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

EU Financial accounts reports

Go to paper

ABSTRACT: Presents updates on the 2000 financial results of several biotechnology and pharmaceutical firms in Europe. Celltech Group Plc; ML Laboratories plc; Pharmagene plc.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for November 11 2014

TradenameApplicantGeneric NamePatent Expiration
INTEGRILIN
Schering
eptifibatide
Nov 11, 2014

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Drug Patent Expirations for November 2014

TradenameApplicantGeneric NamePatent NumberPatent Expiration
ATROVENT HFABoehringer Ingelheimipratropium bromide5,683,677Nov 4, 2014
PALLADONEPurdue Pharma Lphydromorphone hydrochloride6,335,033Nov 4, 2014
QVAR 80Teva Branded Pharmbeclomethasone dipropionate5,683,677Nov 4, 2014
PALLADONEPurdue Pharma Lphydromorphone hydrochloride5,958,452Nov 4, 2014
ZETONNATakeda Gmbhciclesonide5,683,677Nov 4, 2014
ALVESCOTakeda Gmbhciclesonide5,683,677Nov 4, 2014
PALLADONEPurdue Pharma Lphydromorphone hydrochloride5,965,161Nov 4, 2014
QVAR 40Teva Branded Pharmbeclomethasone dipropionate5,683,677Nov 4, 2014
PALLADONEPurdue Pharma Lphydromorphone hydrochloride6,706,281Nov 4, 2014
QNASLTeva Branded Pharmbeclomethasone dipropionate5,683,677Nov 4, 2014
PALLADONEPurdue Pharma Lphydromorphone hydrochloride6,743,442Nov 4, 2014
NOVOLOG PENFILLNovo Nordisk Incinsulin aspart recombinant5,626,566*PEDNov 6, 2014
APTIVUSBoehringer Ingelheimtipranavir6,169,181*PEDNov 6, 2014
INTEGRILINScheringeptifibatide5,686,570Nov 11, 2014
INTEGRILINScheringeptifibatide5,756,451Nov 11, 2014
DICLOFENAC SODIUMFalcon Pharmsdiclofenac sodium5,653,972Nov 16, 2014
DICLOFENAC SODIUMFalcon Pharmsdiclofenac sodium5,603,929Nov 16, 2014
FOSAMAXMerckalendronate sodium5,462,932*PEDNov 17, 2014
SURFAXINDiscovery Labslucinactant5,407,914Nov 17, 2014
FUZEONRocheenfuvirtide6,133,418Nov 17, 2014
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride7,135,571*PEDNov 18, 2014
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride7,135,571*PEDNov 18, 2014
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride7,138,524*PEDNov 18, 2014
CELLCEPTRoche Palomycophenolate mofetil5,688,529Nov 18, 2014
ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride7,135,571*PEDNov 18, 2014
ALLEGRASanofi Aventis Usfexofenadine hydrochloride7,135,571*PEDNov 18, 2014
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride7,138,524*PEDNov 18, 2014
ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride7,135,571*PEDNov 18, 2014
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride7,135,571*PEDNov 18, 2014
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride7,138,524*PEDNov 18, 2014
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride7,138,524*PEDNov 18, 2014
ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride7,138,524*PEDNov 18, 2014
ALLEGRASanofi Aventis Usfexofenadine hydrochloride7,138,524*PEDNov 18, 2014
ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride7,138,524*PEDNov 18, 2014
PRILOSECAstrazenecaomeprazole magnesium5,690,960Nov 25, 2014
VELTINStiefel Gskclindamycin phosphate; tretinoin5,690,923Nov 25, 2014
PRILOSEC OTCAstrazenecaomeprazole magnesium5,690,960Nov 25, 2014
NEXIUM 24HRAstrazeneca Lpesomeprazole magnesium5,690,960Nov 25, 2014
NEXIUM IVAstrazenecaesomeprazole sodium5,877,192*PEDNov 27, 2014
NEXIUMAstrazenecaesomeprazole magnesium6,875,872*PEDNov 27, 2014
VIMOVOHorizon Pharmaesomeprazole magnesium; naproxen6,875,872*PEDNov 27, 2014
NEXIUMAstrazenecaesomeprazole magnesium5,877,192*PEDNov 27, 2014
SULARShionogi Incnisoldipine5,626,874Nov 30, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for November 6 2014

TradenameApplicantGeneric NamePatent Expiration
APTIVUS
Boehringer Ingelheim
tipranavir
Nov 6, 2014
NOVOLOG PENFILL
Novo Nordisk Inc
insulin aspart recombinant
Nov 6, 2014

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for November 4 2014

TradenameApplicantGeneric NamePatent Expiration
ALVESCO
Takeda Gmbh
ciclesonide
Nov 4, 2014
ATROVENT HFA
Boehringer Ingelheim
ipratropium bromide
Nov 4, 2014
PALLADONE
Purdue Pharma Lp
hydromorphone hydrochloride
Nov 4, 2014
QNASL
Teva Branded Pharm
beclomethasone dipropionate
Nov 4, 2014
QVAR 40
Teva Branded Pharm
beclomethasone dipropionate
Nov 4, 2014
QVAR 80
Teva Branded Pharm
beclomethasone dipropionate
Nov 4, 2014
ZETONNA
Takeda Gmbh
ciclesonide
Nov 4, 2014

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for October 22 2014

TradenameApplicantGeneric NamePatent Expiration
PRAVACHOL
Bristol Myers Squibb
pravastatin sodium
Oct 22, 2014
PRAVIGARD PAC (COPACKAGED)
Bristol Myers Squibb
aspirin; pravastatin sodium
Oct 22, 2014

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Conflict of interest in academic research

Go to paper

ABSTRACT: The potential for conflict of interest in research can occur whenever a faculty member's financial interest in an industrial sponsor is sufficient to affect his or her impartiality in interpreting the results of the sponsored project. Owing, in large part, to the role of public funding of research, the appearance of a conflict of interest can be as damaging to the reputation of the investigator and/or university as an actual conflict...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for October 29 2014

TradenameApplicantGeneric NamePatent Expiration
WELCHOL
Daiichi Sankyo
colesevelam hydrochloride
Oct 29, 2014

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for October 28 2014

TradenameApplicantGeneric NamePatent Expiration
IPLEX
Insmed
mecasermin rinfabate recombinant
Oct 28, 2014
RYTHMOL SR
Glaxosmithkline Llc
propafenone hydrochloride
Oct 28, 2014
VELCADE
Millennium Pharms
bortezomib
Oct 28, 2014

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations
FDA Orange Book archives from 2005 to present

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for October 21 2014

TradenameApplicantGeneric NamePatent Expiration
AUBAGIO
Sanofi Aventis Us
teriflunomide
Oct 21, 2014
CYCLOSET
Veroscience
bromocriptine mesylate
Oct 21, 2014
IMODIUM MULTI-SYMPTOM RELIEF
Mcneil
loperamide hydrochloride; simethicone
Oct 21, 2014

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.